Redcare Pharmacy Reports Strong Q3 Growth and Reaffirms Full-Year Guidance

Redcare Pharmacy N.V. announced preliminary third quarter sales figures showing significant growth across all business segments, with total sales increasing 25.2% to €719 million compared to €575 million in the same period last year. The company's strong performance has led management to reaffirm all elements of its full-year guidance, indicating confidence in continued momentum through the remainder of 2025. Both the DACH and International reporting segments achieved over 25% fully organic sales growth, demonstrating balanced expansion across the company's European markets.

Prescription medication sales showed particularly impressive growth, increasing 42.3% to €272 million compared to €191 million in Q3 2024. The German market stood out with Rx sales totaling €126 million, representing an 82.1% year-over-year increase from €69 million in the same quarter last year. This accelerated growth in prescription medications positions the company to achieve at least €500 million in Rx sales for the full year. Non-prescription sales also maintained strong performance, growing 16.7% to €448 million from €383 million in the prior year period.

Year-to-date figures further underscore the company's growth trajectory, with total sales reaching €2.15 billion, representing a 27% increase of €450 million compared to the same period in 2024. Non-Rx sales year-to-date grew 18% to €1.4 billion, while Rx sales in Germany showed remarkable 122% growth to €348 million. The company's customer base expanded by 200,000 active customers during the quarter, reaching 13.7 million total active customers, while customer satisfaction metrics improved significantly with the net promoter score rising to well over 70 compared to 64 in the first half of the current year.

CEO Olaf Heinrich emphasized that growth remains profitable and cash generative, with a solid Q3 EBITDA performance that has already lifted the year-to-date margin to the company's full-year guidance range of 2 to 2.5%. Management confirmed that financial steering remains fully stable throughout the current transition period, with continuity ensured until the appointment of a new CFO. The company will release its full interim report for the third quarter of 2025 on October 29, 2025, providing detailed financial analysis and additional performance metrics. View the original release on www.newmediawire.com for complete information about the quarterly performance.